Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Executive Summary

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

You may also be interested in...



US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible

New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.

Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began

New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.

US FDA Greenlighting Dozens Of New Trials For Coronavirus Therapeutics

In less than three weeks, the number of clinical trials for potential treatments has jumped to 72, according to the FDA’s Coronavirus Treatment Acceleration Program.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel